Formulation Development
Verrica Pharmaceuticals Holds Type A Meeting With FDA for VP-102 for Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced the company held a Type A meeting with the US FDA on June 27, 2022, regarding the path forward for…
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
Soligenix, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial titled Phase 2 Study…
Artelo Biosciences Presents Positive Pre-Clinical Results for Novel FABP5 Inhibitor
Artelo Biosciences, Inc. recently announced Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results titled Discovery and Preclinical Evaluation…
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
Evaxion Biotech A/S recently announced it has selected EVX-03 as the product candidate within its DNA technology platform to target a new indication with planned…
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
Diffusion Pharmaceuticals Inc. recently announced positive effects from its second Oxygenation Trial, the Altitude Trial. “This was a specialized study designed to evaluate TSC’s novel oxygen-enhancing mechanism…
Cullinan Oncology & Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop & Commercialize CLN-081/TAS6417
Cullinan Oncology, Inc. recently announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. (Taiho) signed in May 2022. Per the terms of the agreement….
Silo Pharma Expands License Agreement & Patent Portfolio
Silo Pharma, Inc. recently announced that it has expanded its Commercial Evaluation License Agreement (CELA) with the University of Maryland Baltimore (UMB) for its next generation Liposomal Peptide targeting….
SCYNEXIS Announces Initiation of New Phase 3b Study to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis
SCYNEXIS, Inc. recently announced the initiation and first patient enrolled in a new Phase 3b, open-label, multicenter study (VANQUISH) to evaluate the efficacy, safety and tolerability…
Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
Precision BioSciences Announces In Vivo Gene Editing Collaboration With Novartis
Precision BioSciences, Inc. recently announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma….
Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC
Pasithea Therapeutics Corp. recently announced its acquisition of Alpha-5 integrin, LLC, a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (ALS) and….
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial & Urothelial Cancer Patients
Acrivon Therapeutics, Inc. recently announced the US FDA has cleared the company's Investigational New Drug (IND) application for its lead asset ACR-368 in a Phase…
USPTO Issues Patent Covering Use of XPro for Treatment of CNS Diseases
INmune Bio, Inc. recently announced the issuance of US Pat. No. 11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant…
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
Biomea Fusion, Inc. recently announced the first patient has been dosed in the MM cohort of COVALENT-101, the company’s Phase 1 clinical trial evaluating BMF-219,…
VIVEbiotech Continues Expansion of its Lentiviral Vector Manufacturing Capabilities to Address the Viral Vector Bottleneck
VIVEbiotech, S.L. recently announced its Good Manufacturing Practice (GMP)-accredited new facility is now fully operational after receiving the renewal of its GMP accreditation for a…
EyePoint Pharmaceuticals & OcuMension Therapeutics Announce Approval of NDA for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics recently announced China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ (fluocinolone…
Halberd Creates Subsidiary to Apply Its Patented Technology to Treat Cancer
Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation recently announced the creation of a subgroup of researchers to focus on cancer treatment. ….
Acer Therapeutics & Relief Therapeutics Announce Update on US FDA Review of NDA
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics recently announced the US FDA has issued a Complete Response Letter (CRL) regarding the New Drug…
Valneva & Pfizer Enter Equity Subscription Agreement & Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15…..
Hepion Pharmaceuticals Receives Orphan Drug Status Designation for the Treatment of Hepatocellular Carcinoma
Hepion Pharmaceuticals, Inc. recently announced the US FDA has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment…
